MADRIGAL PHARMACEUTICALS INC
For the period ended Dec 31, 2024. Filed Feb 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 26, 2025
MDGL$432.79+8.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Revenues: | |||
| Product revenue, net | $180,133 | $— | $— |
| Operating expenses: | |||
| Cost of sales | 6,233 | — | — |
| Research and development | 236,718 | 272,350 | 245,441 |
| Selling, general and administrative | 435,057 | 108,146 | 48,130 |
| Total operating expenses | 678,008 | 380,496 | 293,571 |
| Loss from operations | (497,875) | (380,496) | (293,571) |
| Interest income | 46,654 | 19,578 | 2,185 |
| Interest expense | (14,671) | (12,712) | (3,964) |
| Net loss | $(465,892) | $(373,630) | $(295,350) |
| Net loss per common share: | |||
| Basic and diluted net loss per common share | $(21.90) | $(19.99) | $(17.23) |
| Basic and diluted weighted average number of common shares outstanding | 21,272,962 | 18,687,774 | 17,137,201 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.